August 2012
-
Lupin Limited has officially opened its new Center of Excellence for Inhalation Research in Coral Springs, Florida with a ceremony officials from the city and the state of Florida. The new center will employ 45… Read more . . .
-
According to a spokesperson for GlaxoSmithKline, GSK is aiming to hire a total of 100 employees in 2015 and another 30-40 employees in 2016 for a new DPI assembly line at its Zebulon, NC manufacturing… Read more . . .
-
New Zealand-based Smartinhaler maker Adherium (formerly Nexus6) is looking to raise a minimum of A$20 million (~ US$14.7 million) up to a maximum of A$35 million (~US25.7 million) through an initial public offering on the… Read more . . .
-
Intranasal analgesia developer Trigemina Inc. has announced the appointment of Shashidhar “Shashi” Kori as Chief Medical Officer. Trigemina’s TI-114 intranasal oxytocin, is in Phase 2 development for the treatment of migraine headaches; the company is… Read more . . .
-
Florida-based Breckenridge Pharmaceutical has announced the launch of its azelastine HCl nasal spray, a generic version of Meda’s Astelin, after receiving final FDA approval of its ANDA. The product is approved for the treatment of… Read more . . .
-
Discovery Laboratories has announced the completion of a public offering that raised over $40 million as well as the receipt of a $1 million supplement from a Phase 2 Small Business Innovation Research (SBIR) grant… Read more . . .
-
Allergan has confirmed that it submitted an Abbreviated New Drug Application (ANDA) with the FDA for a generic version of United Therapeutics’ Tyvaso treprostinil inhalation solution for the treatment of pulmonary arterial hypertension and says… Read more . . .
-
Two days after Adapt Pharma announced that it had submitted an NDA for Narcan naloxone nasal spray, Indivior has announced that the FDA has accepted its naloxone nasal spray NDA for priority review. Indivior says… Read more . . .
-
Moerae Matrix has initiated a lipopolysaccharide (LPS) challenge study of its MMI-0100 inhaled MAPKAP kinase 2 (MK2) inhibitor to evaluate its safety and tolerability in smokers, the company said. Moerae is developing MMI-0100 as a… Read more . . .
-
Adapt Pharma has submitted an NDA for Narcan naloxone nasal spray for the treatment of opioid overdose to the FDA, the company has announced. In June 2015, Adapt said that it had initiated a rolling… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland